FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

22 letters match. Newest first.

  1. Baxter International Inc.

    Baxter's Round Lake injectable drug plant violated CGMP (manufacturing quality rules), with cephalosporin cross-contamination and sterile processing failures.

    High risk
  2. Bausch & Lomb Inc.

    FDA warns Bausch & Lomb of persistent microbial contamination and poor aseptic controls at its Tampa sterile drug plant.

    High risk
  3. Skytron, LLC

    Skytron marketed four UV disinfection devices without FDA clearance or approval and kept unapproved medical claims after promising to remove them.

    High risk
  4. Simtra BioPharma Solutions

    FDA found contamination risks in Simtra's sterile drug manufacturing in Germany, including microbial recoveries, failed isolator tests, and inadequate decontamination.

    High risk
  5. Revive Rx LLC dba Revive Rx Pharmacy

    FDA warns Revive Rx Pharmacy over insanitary production of sterile compounded drugs, citing contamination risks.

    High risk
  6. Boothwyn Pharmacy LLC

    FDA warns Boothwyn Pharmacy over unapproved compounded animal drugs and falsified endotoxin records.

    High risk
  7. Fagron Compounding Services, LLC dba Fagron Sterile Service

    FDA warns Fagron Sterile Services about unsafe sterile drug production and labeling problems at its Wichita facility.

    High risk
  8. Indoco Remedies Limited

    FDA warned Indoco Remedies over manufacturing quality failures at its Goa plant, including unreliable microbial testing and aseptic processing deficiencies.

    High risk
  9. Regenerative Processing Plant, LLC

    FDA warns Regenerative Processing Plant over unapproved, misbranded Regener-Eyes eye drops and serious sterile manufacturing violations.

    High risk
  10. Jiangsu Hengrui Pharmaceuticals Co., Ltd.

    FDA found data integrity failures and inadequate sterile manufacturing controls at Jiangsu Hengrui Pharmaceuticals' drug facility.

    High risk
  11. Northern VA Compounders PLLC, dba Akina Pharmacy

    FDA warns Akina Pharmacy over unsafe production of compounded drugs and sterility risks.

    High risk
  12. Kimera Labs, Inc.

    FDA warns Kimera Labs over unapproved exosome and amniotic fluid products and serious sterile manufacturing failures.

    High risk
  13. Terragene S.A.

    Terragene S.A. made sterilization indicator devices with complaint-handling and MDR failures and uncleared extended-cycle claims.

    High risk
  14. Southern Tier Home Infusion, Inc. dba Pharmacy Innovations

    FDA warned compounding pharmacy Pharmacy Innovations that its sterile drugs were made under insanitary conditions and without valid patient prescriptions.

    High risk
  15. US Specialty Formulations, LLC

    US Specialty Formulations, a drug compounder registered as an outsourcing facility, made sterile compounded drugs under insanitary conditions.

    High risk
  16. Sagent Pharmaceuticals, Inc.

    FDA found SterRx, acquired by Sagent, made sterile drugs under conditions that risked contamination and lacked sterility assurance.

    High risk
  17. BioLab Sciences, Inc.

    FDA warned BioLab Sciences that its injected amniotic fluid and skin products were unapproved biologics with serious manufacturing violations.

    High risk
  18. Hybrid Pharma, LLC

    FDA warned outsourcing facility Hybrid Pharma of Deerfield Beach, Florida, that sterile compounding violations made its drugs adulterated and unapproved.

    High risk
  19. Brigham and Women’s Hospital Inc.

    Brigham and Women’s Hospital PET drug facility had water leaks and fungal contamination in aseptic areas, FDA says.

    High risk
  20. Med Shop Total Care, Inc.

    FDA warns Med Shop Total Care about insanitary conditions in sterile drug compounding.

    High risk
  21. Surgenex LLC

    FDA warned Surgenex it sold unapproved umbilical cord and amniotic membrane products for injection without a biologics license and with serious manufacturing problems.

    High risk
  22. Hawaii Health Systems Corporation dba Kona Community Hospital Pharmacy

    Kona Community Hospital Pharmacy prepared sterile drugs in insanitary conditions with microbial contamination and facility flaws.

    High risk